Letter/Communication
Tominersen in Adults with Manifest Huntington’s Disease
The New England journal of medicine, Vol.389(23), pp.2203-2205
12/07/2023
DOI: 10.1056/NEJMc2300400
PMID: 38055260
Abstract
Tominersen and Huntington’s DiseaseA trial of tominersen, designed to slow Huntington’s disease progression by lowering levels of huntingtin protein, was stopped prematurely, and an ad hoc analysis of the results at week 69 was carried out.
Details
- Title: Subtitle
- Tominersen in Adults with Manifest Huntington’s Disease
- Creators
- Peter McColganAlpa ThobhaniLauren BoakScott SchobelAlessia Nicotra - Roche (United Kingdom)Giuseppe Palermo - Roche (Switzerland)Dylan Trundell - Roche (United Kingdom)Julian Zhou - Roche (China)Valerie SchlegelPatricia Sanwald DucrayDavid HawellekJonas DornCedric SimillionMichael LindemannVicki Wheelock - University of California, DavisAlexandra DurrKaren Anderson - Georgetown UniversityJeffrey Long - University of Iowa Health CareEdward Wild - University College LondonG Bernhard Landwehrmeyer - Universität UlmBlair Leavitt - University of British ColumbiaSarah Tabrizi - University College LondonRachelle Doody - Roche (Switzerland)
- Resource Type
- Letter/Communication
- Publication Details
- The New England journal of medicine, Vol.389(23), pp.2203-2205
- DOI
- 10.1056/NEJMc2300400
- PMID
- 38055260
- NLM abbreviation
- N Engl J Med
- ISSN
- 0028-4793
- eISSN
- 1533-4406
- Publisher
- Massachusetts Medical Society
- Grant note
- DOI: 10.13039/100004337, name: F. Hoffmann-La Roche Ltd
- Language
- English
- Date published
- 12/07/2023
- Academic Unit
- Psychiatry; Biostatistics
- Record Identifier
- 9984521374102771
Metrics
25 Record Views